GB virus type C infection modulates T-cell activation independently of HIV-1 viral load


Autoria(s): MAIDANA-GIRET, Maria Teresa; SILVA, Tania M.; SAUER, Mariana M.; TOMIYAMA, Helena; LEVI, Jose Eduardo; BASSICHETTO, Katia C.; NISHIYA, Anna; DIAZ, Ricardo S.; SABINO, Ester C.; PALACIOS, Ricardo; KALLAS, Esper Georges
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

19/10/2012

19/10/2012

2009

Resumo

Background: Many clinical studies have suggested a beneficial effect of GB virus type C (GBV-C) on the course of HIV-1 infection, but the mechanisms involved in such amelioration are not clear. As recent evidence has implicated cellular activation in HIV-1 pathogenesis, we investigated the effect of GBV-C viremia on T-cell activation in early HIV-1 infection. Methods: Forty-eight recently infected HIV-1 patients (23 GBV-C viremic) were evaluated for T-cell counts, expanded immunophenotyping GBV-C RNA detection, and HIV-1 viral load. Nonparametric univariate and multivariate analyses were carried out to identify variables associated with cellular activation, including GBV-C status, HIV-1 viral load, T lymphocyte counts, and CD38 and chemokine (C-C motif) receptor 5 (CCR5) surface expression. Finding: We not only confirmed the positive correlation between HIV-1 viral load and the percentage of T cells positive for CD38(+)CD8(+) but also observed that GBV-C viremic patients had a lower percentage of T cells positive for CD38(+)CD4(+), CD38(+)CD8(+), CCR5(+)CD4(+), and CCR5(+)CD8(+) compared with HIV-1-infected patients who were not GBV-C viremic. In regression models, GBV-C RNA(+) status was associated with a reduction in the CD38 on CD4(+) or CD8(+) T cells and CCR5(+) on CD8(+) T cells, independent of the HIV-1 viral load or CD4(+) and CD8(+) T-cell counts. These results were also supported by the lower expression of CD69 and CD25 in GBV-C viremic patients. Interpretation: The association between GBV-C replication and lower T-cell activation may be a key mechanism involved in the protection conferred by this virus against HIV-1 disease progression to immunodeficiency in HIV-1-infected patients. (C) 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins

Brazilian Program for STD and AIDS, Ministry of Health[914/BRA/3014-UNESCO/Kallas]

Sao Paulo City Health Department[2004-0.168.922-7/Kallas]

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[04/15856-9/Diaz]

FAPESP Fundacao de Amparo a Pesquisa do Estado de Sao Paulo[05/01072-9/Levi)]

Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Brazilian Ministry of Education

Identificador

AIDS, v.23, n.17, p.2277-2287, 2009

0269-9370

http://producao.usp.br/handle/BDPI/23191

10.1097/QAD.0b013e32832d7a11

http://dx.doi.org/10.1097/QAD.0b013e32832d7a11

Idioma(s)

eng

Publicador

LIPPINCOTT WILLIAMS & WILKINS

Relação

AIDS

Direitos

closedAccess

Copyright LIPPINCOTT WILLIAMS & WILKINS

Palavras-Chave #activation #CD38 #coinfection #GB virus type C #HIV-1 #T lymphocyte #HEPATITIS-G VIRUS #BLOOD MONONUCLEAR-CELLS #IMMUNE ACTIVATION #ANTIRETROVIRAL THERAPY #LYMPHOCYTE ACTIVATION #SET-POINT #COINFECTION #RNA #PROGRESSION #INDIVIDUALS #Immunology #Infectious Diseases #Virology
Tipo

article

original article

publishedVersion